Literature DB >> 18374769

Surgery for atrial fibrillation in patients with mitral valve disease: results at five years from the International Registry of Atrial Fibrillation Surgery.

Joao Melo1, Teresa Santiago, Carlos Aguiar, Eva Berglin, Michael Knaut, Ottavio Alfieri, Stefano Benussi, Haw Sie, Mathew Williams, Fernando Hornero, Giuseppi Marinelli, Paul Ridley, Enrique Fulquet-Carreras, António Ferreira.   

Abstract

OBJECTIVES: We sought to assess the clinical and survival benefit of atrial fibrillation surgery in patients submitted to mitral valve surgery after stabilization of postoperative rhythm at 1 year.
METHODS: One thousand seven hundred twenty-three patients were enrolled. Patients with follow-up of longer than 1 year (n = 972) were divided into 3 groups according to surface electrocardiographic rhythm during follow-up visits: stable sinus rhythm, stable atrial fibrillation, and intermittent rhythms. Adverse cardiac event incidence and predictors of long-term outcome were compared among the 3 groups.
RESULTS: In-hospital mortality was 2.6%. Risk factors for mortality were the cut-and-sew technique (odds ratio, 8.92; 95% confidence interval, 1.71-46.50; P = .009) and isolated left atrial procedure (odds ratio, 0.16; 95% confidence interval, 0.04-0.56; P = .004). At 1 year, 63.4% patients were in stable sinus rhythm. Stable sinus rhythm was found to be associated with early and late survival (P = .01, log-rank analysis). Multivariate binary logistic regression analysis found that left atrial dimension (odds ratio, 0.97; 95% confidence interval, 0.96-0.99; P = .005) and concomitant coronary revascularization (odds ratio, 0.48; 95% confidence interval, 0.25-0.92; P = .027) were independent predictors of stable sinus rhythm at 1 year after surgical intervention. At 48 months' follow-up, predictors for stable sinus rhythm were biatrial surgical approach and absence of preoperative permanent atrial fibrillation (odds ratio, 3.56; 95% confidence interval, 1.62-7.83; P < .002). Left atrial size (each millimeter) has a borderline statistical significance (odds ratio, 0.97; 95% confidence interval, 0.93-1.00; P = .065). Thromboembolic events were found to be associated with absence of stable sinus rhythm (P = .010, log-rank analysis).
CONCLUSIONS: The achievement of stable sinus rhythm is a predictor of better survival and lower incidence of thromboembolic events. Predictors of stable sinus rhythm were smaller dimensions of the left atrium, biatrial approach, absence of preoperative permanent atrial fibrillation, and absence of concomitant coronary artery bypass grafting.

Entities:  

Mesh:

Year:  2008        PMID: 18374769     DOI: 10.1016/j.jtcvs.2007.08.069

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  14 in total

Review 1.  Prosthetic valve selection for middle-aged patients with aortic stenosis.

Authors:  Joanna Chikwe; Farzan Filsoufi; Alain F Carpentier
Journal:  Nat Rev Cardiol       Date:  2010-11-02       Impact factor: 32.419

2.  A minimally invasive cox-maze procedure: operative technique and results.

Authors:  Anson M Lee; Kal Clark; Marci S Bailey; Abdulhameed Aziz; Richard B Schuessler; Ralph J Damiano
Journal:  Innovations (Phila)       Date:  2010 Jul-Aug

3.  Surgical ablation of atrial fibrillation during mitral-valve surgery.

Authors:  A Marc Gillinov; Annetine C Gelijns; Michael K Parides; Joseph J DeRose; Alan J Moskowitz; Pierre Voisine; Gorav Ailawadi; Denis Bouchard; Peter K Smith; Michael J Mack; Michael A Acker; John C Mullen; Eric A Rose; Helena L Chang; John D Puskas; Jean-Philippe Couderc; Timothy J Gardner; Robin Varghese; Keith A Horvath; Steven F Bolling; Robert E Michler; Nancy L Geller; Deborah D Ascheim; Marissa A Miller; Emilia Bagiella; Ellen G Moquete; Paula Williams; Wendy C Taddei-Peters; Patrick T O'Gara; Eugene H Blackstone; Michael Argenziano
Journal:  N Engl J Med       Date:  2015-03-16       Impact factor: 91.245

4.  Microwave Ablation in Mitral Valve Surgery for Atrial Fibrillation (MAMA).

Authors:  Anders Jönsson; Mika Lehto; Henrik Ahn; Ulf Hermansson; Peter Linde; Anders Ahlsson; Juhani Koistinen; Jukka Savola; Pekka Raatikainen; Martti Lepojärvi; Antero Sahlman; Kalervo Werkkala; Lauri Toivonen; Håkan Walfridsson
Journal:  J Atr Fibrillation       Date:  2012-08-20

5.  Right atrial lesions do not improve the efficacy of a complete left atrial lesion set in the surgical treatment of atrial fibrillation, but they do increase procedural morbidity.

Authors:  Lori K Soni; Sophia R Cedola; Jacob Cogan; Jeffrey Jiang; Jonathan Yang; Hiroo Takayama; Michael Argenziano
Journal:  J Thorac Cardiovasc Surg       Date:  2013-02       Impact factor: 5.209

Review 6.  The surgical treatment of atrial fibrillation.

Authors:  Anson M Lee; Spencer J Melby; Ralph J Damiano
Journal:  Surg Clin North Am       Date:  2009-08       Impact factor: 2.741

7.  Modified Maze Procedure for Atrial Fibrillation as an Adjunct to Elective Cardiac Surgery: Predictors of Mid-Term Recurrence and Echocardiographic Follow-Up.

Authors:  Claudia Loardi; Francesco Alamanni; Fabrizio Veglia; Claudia Galli; Alessandro Parolari; Marco Zanobini
Journal:  Tex Heart Inst J       Date:  2015-08-01

8.  Predictive factors of sustained sinus rhythm and recurrent atrial fibrillation after the maze procedure.

Authors:  Jong Bum Choi; Hyun Kyu Park; Kyung Hwa Kim; Min Ho Kim; Ja Hong Kuh; Mi-Kyung Lee; Sam Youn Lee
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2013-04-09

9.  Outcome of concomitant cox maze procedure with narrow mazes and left atrial volume reduction.

Authors:  Jong Bum Choi; Jong Hun Kim; Byong Ki Cha
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2014-08-05

10.  Concomitant surgical ablation for atrial fibrillation (AF) in patients with significant atrial dilation >55 mm. Worth the effort?

Authors:  Simon Pecha; Samer Hakmi; Irina Subbotina; Stephan Willems; Hermann Reichenspurner; Florian Mathias Wagner
Journal:  J Cardiothorac Surg       Date:  2015-11-14       Impact factor: 1.637

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.